Patrick W G Mallon

Summary

Affiliation: University College Dublin
Country: Ireland

Publications

  1. doi HIV and bone mineral density
    Patrick W G Mallon
    HIV Molecular Research Group, School of Medicine and Medical Sciences, University College Dublin, Ireland
    Curr Opin Infect Dis 23:1-8. 2010
  2. doi Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
  3. ncbi Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, St Vincent s Medical Centre, St Vincent s Hospital, Sydney, Darlinghurst, NSW 2010, Australia
    AIDS Rev 9:3-15. 2007
  4. ncbi Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
  5. doi Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy
    Claudette S Satchell
    HIV Molecular Research Group, School of Medicine and Medical Sciences, University College Dublin, Ireland
    J Infect Dis 204:1202-10. 2011
  6. pmc HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy
    Allison Martin
    The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e77138. 2013
  7. pmc Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
    Allison Martin
    aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint Louis, Paris, France
    AIDS 27:2403-11. 2013
  8. ncbi The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 44:1475-83. 2007
  9. ncbi In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    J Infect Dis 191:1686-96. 2005
  10. ncbi Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005

Detail Information

Publications29

  1. doi HIV and bone mineral density
    Patrick W G Mallon
    HIV Molecular Research Group, School of Medicine and Medical Sciences, University College Dublin, Ireland
    Curr Opin Infect Dis 23:1-8. 2010
    ..This review details the clinical aspects and pathogenesis of low bone mineral density (BMD) in HIV, discusses broad management issues and outlines areas in which our understanding of this condition is incomplete...
  2. doi Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
    ..Rosiglitazone (RSG), a PPARgamma agonist, improves congenital lipoatrophy but not HIV lipoatrophy...
  3. ncbi Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, St Vincent s Medical Centre, St Vincent s Hospital, Sydney, Darlinghurst, NSW 2010, Australia
    AIDS Rev 9:3-15. 2007
    ..This review will summarize what is known of the molecular mechanisms underlying HIV-associated lipodystrophy. A greater understanding of these mechanisms is essential if effective therapeutic options are to be found...
  4. ncbi Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
    ..To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (PI)-treated men with hypercholesterolaemia...
  5. doi Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy
    Claudette S Satchell
    HIV Molecular Research Group, School of Medicine and Medical Sciences, University College Dublin, Ireland
    J Infect Dis 204:1202-10. 2011
    ..Given the role of platelet aggregation in thrombus formation in MI and the reversible nature of the abacavir association, we hypothesized that patients treated with abacavir would have increased platelet reactivity...
  6. pmc HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy
    Allison Martin
    The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e77138. 2013
    ....
  7. pmc Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
    Allison Martin
    aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint Louis, Paris, France
    AIDS 27:2403-11. 2013
    ....
  8. ncbi The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 44:1475-83. 2007
    ..Ritonavir-boosted double-protease inhibitor (PI)-only regimens are such an option but are prone to pharmacokinetic interactions...
  9. ncbi In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    J Infect Dis 191:1686-96. 2005
    ..The effects of this mitochondrial dysfunction on lipid metabolism, at a molecular level in vivo, have not been described...
  10. ncbi Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005
    ..This study sought to investigate the effects of rosiglitazone on endothelial function and other markers of cardiovascular risk in patients with HIV-related lipoatrophy...
  11. ncbi Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Antivir Ther 10:M101-8. 2005
    ..Careful collection and processing of adequate biological samples, robust laboratory processes and assays, and appropriate study design can help overcome many of these difficulties...
  12. ncbi Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
    J Antimicrob Chemother 56:380-7. 2005
    ..The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals...
  13. doi Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study
    Aoife G Cotter
    HIV Molecular Research Group, School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland
    J Clin Endocrinol Metab 98:1659-66. 2013
    ..In virologically suppressed, antiretroviral-treated patients, the effect of switching to tenofovir (TDF) on bone biomarkers compared to patients remaining on stable antiretroviral therapy is unknown...
  14. doi The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation
    Eoin R Feeney
    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Ireland
    J Infect Dis 207:628-37. 2013
    ..In vitro, HIV impairs monocyte-macrophage cholesterol efflux, a major determinant of circulating HDL-c, by increasing ABCA1 degradation, with compensatory upregulation of ABCA1 messenger RNA (mRNA)...
  15. doi Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports
    David P Gallagher
    Department of 1Infectious Diseases, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
    Clin Infect Dis 47:e36-8. 2008
    ..Discontinuation of atazanavir in both cases resulted in a reduction in the QT interval and cessation of arrhythmia. We concluded that atazanavir contributed to prolonged corrected QT interval and subsequent ventricular tachycardia...
  16. ncbi Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 38:156-62. 2005
    ....
  17. ncbi Therapeutic approaches to combating lipoatrophy: do they work?
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria St, Darlinghurst NSW 2010, Sydney, Australia
    J Antimicrob Chemother 55:612-5. 2005
    ....
  18. ncbi Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation
    Eoin R Feeney
    School of Medicine and Medical Sciences, University College Dublin, C339 Health Sciences Building, Dublin 4, Ireland
    Curr Pharm Des 16:3339-51. 2010
    ..Using the example of HIV-associated lipodystrophy (HIVLD) as a model of clinical MtT we discuss management strategies and the potential for these toxicities to impact on future ARV development...
  19. doi Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA
    Eoin R Feeney
    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    AIDS 26:2165-74. 2012
    ..No randomized study has prospectively followed subcutaneous adipose tissue mitochondrial DNA (mtDNA) changes when starting thymidine nucleoside reverse transcriptase inhibitors (tNRTIs)...
  20. doi Therapeutic options for low bone mineral density in HIV-infected subjects
    Aoife G Cotter
    HIV Molecular Research Group, University College Dublin, Clinical Research Centre, Nelson St, Dublin, Ireland
    Curr HIV/AIDS Rep 9:148-59. 2012
    ..Low bone mineral density (BMD) is more common in those with HIV infection and this review will outline therapeutic options for the management of low bone mineral density relevant to HIV-infected populations...
  21. doi HIV infection and bone disease: implications for an aging population
    Aoife G Cotter
    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin 7, Ireland
    Sex Health 8:493-501. 2011
    ..This review will detail the epidemiology, pathogenesis, diagnosis and management of osteoporosis and low BMD in HIV-infected patients, with particular emphasis on aging...
  22. ncbi 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 8-11 February 2004: where are the breakthroughs?
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst 2010, Sydney, Australia
    J HIV Ther 9:19-22. 2004
  23. ncbi HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, St Vincent s Hospital Medical Centre, 376 Victoria Street, Sydney NSW 2010, Australia
    Curr Diab Rep 2:116-24. 2002
    ..Treatment strategies, normally successful in the general population, have generally been less effective in this group of people, in which the detrimental effects of the antiretroviral medications are ongoing...
  24. doi Platelet function and HIV: a case-control study
    Claudette S Satchell
    School of Medicine and Medical Sciences, University College Dublin, Ireland
    AIDS 24:649-57. 2010
    ..Although platelets mediate arterial thrombosis, central to myocardial infarction, data on platelet function in HIV infection are lacking. We hypothesized that HIV-infected patients would have altered platelet reactivity...
  25. pmc Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naïve and memory T-cell subsets
    Willard Tinago
    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe
    PLoS ONE 9:e97011. 2014
    ..Although retention of naïve CD4+ T-cells is thought to predict better immune responses, relationships between CD4+ and CD8+ T-cell subsets and CD4+/CD8+ ratio have not been well described...
  26. pmc Antiretroviral therapy and dyslipidaemia: unlocking the code
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, St Vincent s Medical Centre, Sydney, Australia unsw edu au
    PLoS Med 3:e85. 2006
  27. ncbi Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, St Vincent s Hospital Medical Centre, University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
    J Clin Virol 26:223-7. 2003
    ..Nevertheless, it has a potentially important role to play in the management of HIV-infected patients, with the aim of limiting toxicity, optimising antiviral effect and decreasing virological failure and emergence of viral resistance...
  28. pmc HIV and HAART-Associated Dyslipidemia
    Eoin R Feeney
    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Open Cardiovasc Med J 5:49-63. 2011
    ....
  29. doi High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients
    Aoife G Cotter
    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Ireland
    AIDS 25:867-9. 2011
    ..In this cohort, HDL-c contributed more to cardiovascular risk than smoking, total cholesterol, systolic blood pressure (SBP) and sex...